CoChat

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity

Jepsen, Mathies M., Christensen, Mikkel B. · 2021 · Expert Opinion on Emerging Drugs

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Introduction: Obesity is a growing threat to public health, increasing risks of numerous diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 billion individuals will have obesity in 2030, corresponding to almost 2.5 times the number of adults currently living with diabetes. There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes. Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54,728,518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456,906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706). Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of novel anti-obesity compounds.

Overview

Integrity signals

Registry

Crossref · 10.1080/14728214.2021.1947240

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Research works printed but not linked: 19

  1. van Rijswijk A-S, 2021, Obes Surg
  2. Kang JH, 2017, Medicine (Baltimore), 96
  3. Kelly T, 1986, Int J Obes, 10, 7
  4. Cawley J, 2012, J Health Econ, 42, S90
  5. Moonschi FH, 2018, Acta Diabetol, 10
  6. Mathiesen DS, 2019, Int J Mol Sci, 21
  7. Fu W, 2013, Front Aging Neurosci, 13, 5
  8. Griffith DA, 2020, bioRxiv
  9. Lau J, 2015, J Med Chem, 155
  10. Wilding JPH, 2021, N Engl J Med, 384, NEJMoa2032183
  11. CT 868 - AdisInsight [Internet]. [cited 2021 Jan 29]. Available from: https://adisinsight.springer.com/drugs/800053575
  12. 2018, Mol Metab, 33, 3
  13. Ingelheim B, Pharma Z Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to phase 2 clinical testing in obesity/diabetes [Internet]. boehringer-ingelheim.us. [cited 2021 Feb 5]. Available from: https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi
  14. BI 456906 - AdisInsight [Internet]. [cited 2021 Feb 16]. Available from: https://adisinsight.springer.com/drugs/800049709
  15. 2019, Hepatology, 70, 1
  16. HM 15211 - AdisInsight [Internet]. [cited 2021 Jan 29]. Available from: https://adisinsight.springer.com/drugs/800049366
  17. Jph W,SJ, 2021, Obes Rev Off J Int Assoc Study Obes, 22
  18. Jp W, 2016, Diabetes Obes Metab, 18
  19. 2021, Cell Rep Med, 30, 100263

Cited by

See all 96

Metadata

Authors
Jepsen, M. M., & Christensen, M. B.
Affiliations
University of Copenhagen (DK)
Corresponding author
Christensen, Mikkel B.
Venue
Expert Opinion on Emerging Drugs
Published
2021-07-03
Volume
26
Issue
3
Pages
231-243
ISSN
  • 1472-8214 (ISSN-L)
  • 1744-7623
OpenAlex
W3176790398
Cited by
96
References
65
Citations by year
2026: 11 · 2025: 20 · 2024: 20 · 2023: 29 · 2022: 11 · 2021: 5
FWCI
9.48
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Emerging Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, GLP-1 receptor agonists, anti-obesity drugs, semaglutide, tirzepatide, oxyntomodulin, amylin, glucagon, energy balance, drug development, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Humans, Hypoglycemic Agents, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. https://app.cochat.ai/papers/10.1080/14728214.2021.1947240
The paper
Jepsen, M. M., & Christensen, M. B. (2021). Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2021.1947240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.